Drug intelligence / Profile preview

obetinib

Development stage: Unknown
Lead developer: DTRM Biopharma
Modality: Small Molecules
Administration: Oral

Overview

Obetinib (DTRM-031) is an orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Developed by DTRM Biopharma, it is designed to treat various B-cell malignancies by blocking the B-cell receptor (BCR) signaling pathway, which is critical for the survival and proliferation of malignant B cells. Obetinib is particularly noted for its potential in treating central nervous system (CNS) lymphomas, often evaluated in combination with other therapies such as CAR-T cells (e.g., regorafenapyr), autologous hematopoietic stem cell transplantation (ASCT), and checkpoint inhibitors (e.g., sintilimab). It is currently being investigated in clinical trials for primary and relapsed/refractory CNS diffuse large B-cell lymphoma (DLBCL).

Other names: obetinib奥贝替尼

Targets

BTK (Bruton tyrosine kinase)

Beyond the preview

Go deeper on obetinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on obetinib.

Explore the full profile